Immunome, Inc. (NASDAQ:IMNM) CEO Clay B. Siegall Purchases 150,000 Shares

Immunome, Inc. (NASDAQ:IMNM) CEO Clay B. Siegall acquired 150,000 shares of the stock in a transaction that occurred on Friday, January 31st. The shares were bought at an average price of $7.75 per share, with a total value of $1,162,500.00. Following the completion of the purchase, the chief executive officer now owns 669,636 shares in the company, valued at $5,189,679. The trade was a 28.87 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Immunome Stock Performance

NASDAQ:IMNM opened at $11.08 on Wednesday. Immunome, Inc. has a 1 year low of $8.97 and a 1 year high of $30.96. The stock has a market cap of $691.61 million, a price-to-earnings ratio of -1.37 and a beta of 1.90. The business has a fifty day moving average of $11.34 and a 200-day moving average of $12.67.

Analyst Upgrades and Downgrades

IMNM has been the subject of a number of recent research reports. Piper Sandler lowered their price objective on Immunome from $23.00 to $21.00 and set an “overweight” rating for the company in a research note on Thursday, November 14th. Stephens initiated coverage on Immunome in a research note on Friday, November 8th. They set an “overweight” rating and a $30.00 price objective for the company. Finally, Wedbush restated an “outperform” rating and set a $33.00 price objective on shares of Immunome in a research note on Monday, January 13th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $28.60.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. FMR LLC grew its stake in shares of Immunome by 0.3% in the third quarter. FMR LLC now owns 4,224,700 shares of the company’s stock worth $61,765,000 after purchasing an additional 13,757 shares in the last quarter. Janus Henderson Group PLC grew its stake in shares of Immunome by 10.3% in the third quarter. Janus Henderson Group PLC now owns 3,488,121 shares of the company’s stock worth $50,971,000 after purchasing an additional 324,614 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Immunome by 13.6% in the third quarter. Geode Capital Management LLC now owns 1,207,455 shares of the company’s stock valued at $17,657,000 after buying an additional 144,557 shares during the period. Victory Capital Management Inc. lifted its holdings in shares of Immunome by 48.1% in the third quarter. Victory Capital Management Inc. now owns 730,785 shares of the company’s stock valued at $10,684,000 after buying an additional 237,497 shares during the period. Finally, Point72 Asset Management L.P. lifted its holdings in shares of Immunome by 22.2% in the third quarter. Point72 Asset Management L.P. now owns 470,647 shares of the company’s stock valued at $6,881,000 after buying an additional 85,580 shares during the period. Institutional investors own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.